Pathways to Silencing Psoriasis: Remission or Cure?
Amphitheatre B
Date: Friday 20 September 2019, 13.00-14.30
Room: Amphitheatre B
Learning objectives
After this session, participants should be able to:
• Recognize the clinical implications of the pathophysiology of psoriasis and its comorbidities
• Devise strategies for treatment individualization and optimization based on the patient needs, genetic predisposition, and pharmacoeconomic considerations
• Critique the role of disease modification and hypothesize how treatment optimization strategies could be utilized for optimal long-term patient outcomes
Program
| 13.00-13.05 | Welcome and introduction Jo Lambert (Ghent, Belgium) |
| 13.05-13.25 | The role of IL-23 in the pathogenesis of psoriasis – a common pathway in immune-mediated inflammatory diseases Jörg Prinz (Munich, Germany) |
| 13.25-13.45 | Optimizing psoriasis care of patients with comorbidity Jo Lambert (Ghent, Belgium) |
| 13.45-14.05 | Future of psoriasis: can lasting improvement be achieved in psoriasis care? Carle Paul (Toulouse, France) |
| 14.05-14.25 | Interactive Q&A session
|
| 14.25-14.30 | Concluding remarks and close of the meeting Jörg Prinz (Munich, Germany) |
Sponsored Symposium